OBJECTIVES: We assessed mortality associated with immunologic and virologic patterns of response at 6 months of highly active antiretroviral therapy (HAART) in HIV-infected individuals from resource-limited countries in Africa and South America. METHODS: Patients who initiated HAART between 1996 and 2007, aged 16 years or older, and had at least 1 measurement (HIV-1 RNA plasma viral load or CD4 cell count) at 6 months of therapy (3-9 month window) were included. Therapy response was categorized as complete, discordant (virologic only or immunologic only), and absent. Associations between 6-month response to therapy and all-cause mortality were assessed by Cox proportional hazards regression. Robust standard errors were calculated to account for intrasite correlation. RESULTS: A total of 7160 patients, corresponding to 15,107 person-years, were analyzed. In multivariable analysis adjusted for age at HAART initiation, baseline clinical stage and CD4 cell count, year of HAART initiation, clinic, occurrence of an AIDS-defining condition within the first 6 months of treatment, and discordant and absent responses were associated with increased risk of death. CONCLUSIONS: Similar to reports from high-income countries, discordant immunologic and virologic responses were associated with intermediate risk of death compared with complete and no response in this large cohort of HIV-1 patients from resource-limited countries. Our results support a recommendation for wider availability of plasma viral load testing to monitor antiretroviral therapy in these settings.
OBJECTIVES: We assessed mortality associated with immunologic and virologic patterns of response at 6 months of highly active antiretroviral therapy (HAART) in HIV-infected individuals from resource-limited countries in Africa and South America. METHODS:Patients who initiated HAART between 1996 and 2007, aged 16 years or older, and had at least 1 measurement (HIV-1 RNA plasma viral load or CD4 cell count) at 6 months of therapy (3-9 month window) were included. Therapy response was categorized as complete, discordant (virologic only or immunologic only), and absent. Associations between 6-month response to therapy and all-cause mortality were assessed by Cox proportional hazards regression. Robust standard errors were calculated to account for intrasite correlation. RESULTS: A total of 7160 patients, corresponding to 15,107 person-years, were analyzed. In multivariable analysis adjusted for age at HAART initiation, baseline clinical stage and CD4 cell count, year of HAART initiation, clinic, occurrence of an AIDS-defining condition within the first 6 months of treatment, and discordant and absent responses were associated with increased risk of death. CONCLUSIONS: Similar to reports from high-income countries, discordant immunologic and virologic responses were associated with intermediate risk of death compared with complete and no response in this large cohort of HIV-1patients from resource-limited countries. Our results support a recommendation for wider availability of plasma viral load testing to monitor antiretroviral therapy in these settings.
Authors: Susan A Sufka; Guido Ferrari; Victoria E Gryszowka; Terri Wrin; Susan A Fiscus; Georgia D Tomaras; Herman F Staats; Dhavalkumar D Patel; Gregory D Sempowski; Nicholas S Hellmann; Kent J Weinhold; Charles B Hicks Journal: J Infect Dis Date: 2003-03-13 Impact factor: 5.226
Authors: G Santoro-Lopes; L H Harrison; M D Tavares; A Xexéo; A C Dos Santos; M Schechter Journal: AIDS Res Hum Retroviruses Date: 2000-07-01 Impact factor: 2.205
Authors: Robert S Hogg; Katherine Heath; David Bangsberg; Benita Yip; Natasha Press; Michael V O'Shaughnessy; Julio S G Montaner Journal: AIDS Date: 2002-05-03 Impact factor: 4.177
Authors: S G Deeks; T Wrin; T Liegler; R Hoh; M Hayden; J D Barbour; N S Hellmann; C J Petropoulos; J M McCune; M K Hellerstein; R M Grant Journal: N Engl J Med Date: 2001-02-15 Impact factor: 91.245
Authors: Maya L Petersen; Mark J van der Laan; Sonia Napravnik; Joseph J Eron; Richard D Moore; Steven G Deeks Journal: AIDS Date: 2008-10-18 Impact factor: 4.177
Authors: Kara B Anthony; Christian Yoder; Julia A Metcalf; Rebecca DerSimonian; Jan M Orenstein; Randy A Stevens; Judy Falloon; Michael A Polis; H Clifford Lane; Irini Sereti Journal: J Acquir Immune Defic Syndr Date: 2003-06-01 Impact factor: 3.731
Authors: Evan Wood; Robert S Hogg; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner Journal: Ann Intern Med Date: 2003-11-18 Impact factor: 25.391
Authors: Michael Abouyannis; Joris Menten; Agnes Kiragga; Lutgarde Lynen; Gavin Robertson; Barbara Castelnuovo; Yukari C Manabe; Steven J Reynolds; Lesley Roberts Journal: AIDS Date: 2011-08-24 Impact factor: 4.177
Authors: Steven J Reynolds; Joseph B Sempa; Agnes N Kiragga; Kevin Newell; Gertrude Nakigozi; Ronald Galiwango; Ron Gray; Thomas C Quinn; David Serwadda; Larry Chang Journal: AIDS Patient Care STDS Date: 2014-10-07 Impact factor: 5.078
Authors: Sabine M Hermans; Agnes N Kiragga; Petra Schaefer; Andrew Kambugu; Andy I M Hoepelman; Yukari C Manabe Journal: PLoS One Date: 2010-05-07 Impact factor: 3.240
Authors: Aaron A R Tobian; Mary K Grabowski; David Serwadda; Kevin Newell; Paschal Ssebbowa; Veronica Franco; Fred Nalugoda; Maria J Wawer; Ronald H Gray; Thomas C Quinn; Steven J Reynolds Journal: J Infect Dis Date: 2013-06-28 Impact factor: 5.226